NNVC — NANOVIRICIDES, INC.

—
NYSE · Health Care · Pharmaceuticals · CIK 1379006 ·
Last close
$1.16
Market Cap
$29.61M
52W High
$1.93
52W Low
$0.85
ADV30
178,270
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -5,768,489 -5,742,936 9,562,717 2,575,227 3,150,427
Jun 2026 0 — -2,246,284 -2,223,399 9,873,614 2,794,110 1,190,724
Mar 2026 0 — -2,030,218 -1,989,333 10,219,004 3,213,256 1,065,407
Dec 2025 0 — -2,233,174 -2,220,719 12,267,640 5,150,580 1,195,925

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,276,000
Investing CF
$-94,516
Financing CF
$8,041,182
CapEx
$-94,517
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-10-05

Balance + Analyst (yfinance extras)

Retained Earnings
$-154,836,971
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-8,102,618
Pretax Income TTM
$-8,090,991
Interest Exp TTM
$0
Analysts
2

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 0 -8,306,361 -8,218,509 9,873,614 1,190,724 8,682,890 -7,696,015
Jun 2025 0 -9,591,645 -9,466,966 8,824,085 1,306,519 7,517,566 -8,478,679
Jun 2024 0 -8,516,111 -8,294,146 12,822,853 1,358,776 11,464,077 -6,315,507
Jun 2023 0 -8,943,468 -8,588,573 16,899,880 2,034,250 14,865,630 -5,670,051

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-8,218,509
OpCashFlow TTM
—
Assets (Latest)
$10,219,004
Forward EPS
$-0.35

Peers — same industry

TickerNameMarket CapLastDaily %
PRRUF IMMUTEP Ltd $29.47M $0.02 —
RLFTY MindMaze Therapeutics Holding SA $30.24M $0.18 —
AYTU AYTU BIOPHARMA, INC $28.91M $2.66 —
RDPTF Radiopharm Theranostics Ltd $28.89M $0.01 —
PMN ProMIS Neurosciences Inc. $28.88M $3.21 —

News headlines (Yahoo Finance, 1h cache)

NanoViricides: Fiscal Q1 Earnings Snapshot
2026-11-17 14:13 · Yahoo
NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease,
2026-11-17 13:45 · Yahoo
An Investigational Drug to Tackle Measles Outbreaks
2026-11-10 13:45 · Yahoo
As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides
2026-10-27 13:15 · Yahoo
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way fo
2026-10-20 12:45 · Yahoo
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
2026-10-13 12:45 · Yahoo
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
2026-10-06 12:45 · Yahoo
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
2026-10-05 12:45 · Yahoo
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
2026-09-29 12:45 · Yahoo
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
2026-09-28 12:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.